B Cell Receptor-Responsive miR-141 Enhances Epstein-Barr Virus Lytic Cycle via FOXO3 Inhibition

Yan Chen; Devin N. Fachko; Nikita S. Ivanov; Rebecca L. Skalsky

doi:10.1128/mSphere.00093-21

mSphere (Apr 2021)

B Cell Receptor-Responsive miR-141 Enhances Epstein-Barr Virus Lytic Cycle via FOXO3 Inhibition

Yan Chen,
Devin N. Fachko,
Nikita S. Ivanov,
Rebecca L. Skalsky

Affiliations

Yan Chen: Vaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, USA
Devin N. Fachko: Vaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, USA
Nikita S. Ivanov: Vaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, USA
Rebecca L. Skalsky: ORCiD; Vaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, USA

DOI: https://doi.org/10.1128/mSphere.00093-21
Journal volume & issue: Vol. 6, no. 2

Abstract

Read online

EBV is a human pathogen associated with several malignancies. A key aspect of lifelong virus persistence is the ability to switch between latent and lytic replication modes.

Published in mSphere

ISSN: 2379-5042 (Online)
Publisher: American Society for Microbiology
Country of publisher: United States
LCC subjects: Science: Microbiology
Website: https://journals.asm.org/journal/msphere

About the journal